Ulcerative colitis is a common inflammatory disease of the colon characterized by inflammation and ulceration of the large bowel and rectum. The condition impairs the ability of the large bowel to absorb water which results in diarrhea, the main symptom of the condition.
Ulcerative colitis is a relapsing and remitting condition, meaning symptoms can die down for long periods but then flare-up from time to time. These flare-ups can be sudden and severe. During a period of relapse, symptoms may include bloody diarrhea, abdominal pain and a sudden urge to defecate. Other symptoms include wind, loss of appetite, weight loss, fever and fatigue.
Currently, there is no cure for the condition apart from surgery. However, certain treatments such as corticosteroids or immunosuppressants may be used to ease symptoms by reducing inflammation. Surgery for severe ulcerative colitis that does not respond to treatment involves completely removing the large bowel and re-routing the small bowel so that waste can still be expelled. This procedure is called a colectomy.
In the UK, the incidence of ulcerative colitis is around 1 in 500 and the condition is equally common among males and females. Symptoms can develop at any age, but onset usually occurs between 15 and 30 years of age.
What is Ulcerative Colitis?
Ulcerative colitis is a chronic condition that affects the large intestines, particularly the colon. It is classified as one of the two inflammatory bowel diseases along with Crohn’s disease.
In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans.
Scientists from the Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago demonstrated that a nanotherapy reduces intestinal inflammation and shrinks lesions in a rodent model of severe Crohn's disease.
For all their importance as a breakthrough treatment, the cancer immunotherapies known as checkpoint inhibitors still only benefit a small minority of patients, perhaps 15 percent across different types of cancer.
A method that instructs immune system cells to help repair damaged tissues in the intestine has been developed by researchers at KU Leuven and Seoul National University.
A healthy person has a general balance of good and bad bacteria. But that balance is thrown off when someone gets sick.
The Crohn's & Colitis Foundation, the leading non-profit organization focused on both research and patient support for inflammatory bowel disease (IBD), has entered into a partnership with LifeArc, an independent medical research charity that advances translation of early science into health care treatments or diagnostics, to potentially develop the first clinical lab test to predict disease course in pediatric patients with Crohn's disease and response to treatment.
As reported in Nature Communications, researchers from Cleveland Clinic's Lerner Research Institute have developed a novel, patient-derived model of ulcerative colitis, which will help advance studies into new treatments for the chronic inflammatory bowel disease.
Using genetic data from nearly 30,000 people, Mount Sinai researchers have built risk scores from a combination of datasets representing distinct ancestral populations that improve prediction of risk for inflammatory bowel diseases (IBD) including Crohn's disease and ulcerative colitis. The study was published in Gastroenterology on December 24.
A potential preventive treatment for Crohn's disease, a form of inflammatory bowel disease, has been demonstrated in a mouse model and using immune-reactive T cells from patients with Crohn's disease.
Could number two be number one when it comes to combating recurrent Clostridium difficile (CDI) infections?Using genetic material analysis and machine learning, UBC researchers have pinpointed several key factors to ensure successful fecal microbiota transplants (FMT), which have proven successful in treating bacterial infections in the gut including illnesses like C. difficile, Crohn's Disease, Colitis and even obesity, explains lead author Negin Kazemian.
Blood clots are the biggest cause of death in patients with inflammatory bowel disease (IBD) ─ ulcerative colitis or Crohn's disease. In a retrospective study recently published in the journal Gastroenterology, Cedars-Sinai investigators found that a combination of rare and common genetic variants in some IBD patients significantly increased their risk of developing clot-causing thromboembolic diseases.
New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.
The Pediatric IBD Foundation, ImproveCareNow, and the Critical Path Institute (C-Path) are proud to announce a collaboration establishing the Children's Registry for the Advancement of Therapeutics (CREATE™).
Using sophisticated 3D genomic mapping and integrating with public data resulting from genome-wide association studies, researchers at Children's Hospital of Philadelphia have found significant genetic correlations between inflammatory bowel disease and stress and depression.
Bacteria from the mouth could hold clues to understanding – and potentially treating – severe ulcerative colitis, a painful bowel disease.
A new study, published inGut, has found depression is more common among people with Crohn's disease or ulcerative colitis in the years before they are diagnosed with these bowel conditions.
In the piece about the AstraZeneca vaccine trial subject who suffered severe spinal cord inflammation, that person was repeatedly referred to as a "patient" ("NIH 'Very Concerned' About Serious Side Effect in Coronavirus Vaccine Trial," Sept. 14).
Celiac disease is an immune disease of the intestine that affects more than 1% of the population. It is characterised by gluten intolerance that causes inflammation of the gut, abdominal pain and diarrhoea, and can lead to weight loss and deficiencies among patients.
People with celiac disease may find themselves more comfortable with extra Thanksgiving turkey dinners.An international team of researchers led by McMaster University has found that tryptophan, an amino acid present in high amounts in turkey, along with some probiotics, may help them heal and respond better to a gluten-free diet.
In many patients with Crohn's disease, abdominal fat migrates to the wall of the inflamed small intestines. What prompts the fat tissue to "creep" through the abdomen and wrap around the intestines of many patients with this inflammatory bowel disease (IBD) has been an enduring mystery.